- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- September 2024
- 78 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2022
- 54 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Shigellosis is an infectious disease caused by a group of bacteria known as Shigella. Treatment of shigellosis typically involves antibiotics, such as ciprofloxacin, ceftriaxone, and azithromycin. The Shigellosis Drug market is a subset of the larger Infectious Diseases Drugs market, which includes drugs used to treat a variety of bacterial, viral, and fungal infections.
The Shigellosis Drug market is composed of a variety of pharmaceutical companies that develop and manufacture drugs to treat shigellosis. These companies are typically involved in the research and development of new drugs, as well as the production and distribution of existing drugs. Companies in the Shigellosis Drug market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more